Tarsus Pharmaceuticals, Inc. (TARS) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Irvine, CA, United States. Le PDG actuel est Bobak R. Azamian.
TARS a date d'introduction en bourse 2020-10-16, 323 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $3.14B.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Irvine, California, focused on developing novel therapeutic candidates for ophthalmic and dermatological conditions. The company's lead product candidate, TP-03, is in Phase III clinical trials for treating blepharitis caused by Demodex mite infestation and meibomian gland disease. Tarsus is also advancing a pipeline that includes TP-04 for rosacea treatment and TP-05 for Lyme disease prophylaxis and malaria reduction, alongside the development of lotilaner for multiple therapeutic applications across ophthalmology, dermatology, and other disease areas. Founded in 2016, the company is positioned to address significant unmet medical needs in eye care and skin conditions.
